Muhammad Rauf, Ehsan ul Haq, Ammad Qayyum
Aim: To determine the relationship between glycan hemoglobin and short-term mortality after myocardial infarction. Study design: Prospective case-control type of study Place and duration: In the Medicine Unit I and Cardiology department of Nishter Hospital Multan for one year duration from January 2019 to January 2020. Patients and methods: Initially, 955 patients with myocardial infarction (MI) were included in the study. Approximately 201 patients withdrew from the study due to premature deaths (n = 17) falling under impaired glucose tolerance during the next oral glucose tolerance test (OGTT) (n = 67), with dyslipidemia during the studies (n = 20) or due to other comorbidities such as chronic renal failure (n = 34), stroke (n = 42) or previous history of MI (n = 21). The remaining 754 patients were divided into two groups: diabetes and non-diabetics, depending on the results of the oral glucose tolerance test. HbA1C glycosylated hemoglobin was measured in all patients. After 30 days, these patients were followed and the number of deaths estimated. Data were analyzed using SPSS version 17.0. Results: In non-diabetic patients, an increase in HbA1C (> 5.5%) resulted in a significant increase in deaths, while HbA1C in the diabetic group was fatal within a month of acute myocardial infarction. Conclusion: High levels of HbA1C in diabetic and non-diabetic patients increase the risk of short-term mortality after acute myocardial infarction. Key words: glycan hemoglobin, oral glucose tolerance test.